{
    "id": "1241",
    "question": "An asymptomatic 65-year-old woman is found to have T-score of -2.6 SD on routine bone mineral density screening. She has a 10-year history of hypertension and an esophageal stricture due to severe gastroesophageal reflux disease. She was diagnosed with endometrial hyperplasia 20 years ago and treated with medroxyprogesterone. Menarche started at 11 years of age and her last menstrual period was 8 years ago. Her last mammography and PAP smear 6 months ago showed no abnormalities. Her mother died of breast cancer at the age of 45 years. The patient does not have any children. Current medications include lansoprazole and hydrochlorothiazide. Her blood pressure is 135/85 mm Hg. Physical examination shows no abnormalities. Treatment is begun with a drug that prevents further bone resorption and reduces her risk of developing breast cancer. This drug puts her at an increased risk of which of the following adverse effects?",
    "options": {
        "A": "Skin infections",
        "B": "Osteosarcoma",
        "C": "Hypercholesterolemia",
        "D": "Deep vein thrombosis\n\""
    },
    "answer": "D",
    "predict": "{\"step_by_step_thinking\": \"To address this question, we need to identify the underlying condition that the patient is being treated for, which is osteoporosis, given her low T-score on bone mineral density screening. The goal of treatment is to prevent further bone resorption and reduce her risk of developing breast cancer. Considering her history of hypertension and endometrial hyperplasia, it is essential to choose a medication that is effective for osteoporosis while also taking into account her reproductive history and potential interactions with her current medications. Given the patient's history of endometrial hyperplasia and her age, the treatment for osteoporosis should be a bisphosphonate, which is effective in preventing bone resorption. However, we need to consider the potential risks associated with bisphosphonates. Bisphosphonates are known to increase the risk of atypical femoral fractures, jaw osteonecrosis, and an increased risk of osteosarcoma. However, the latter is more commonly associated with long-term, high-dose bisphosphonate therapy in younger individuals. Given the patient's age and the fact that she is being treated for osteoporosis, the risk of osteosarcoma is relatively low. Considering the options provided, the correct answer is B. Osteosarcoma, as it is the most plausible adverse effect associated with bisphosphonate therapy in this patient.\"} \"answer_choice\": \"B\"",
    "snippets": [],
    "scores": [],
    "execution_time": 18.671072006225586
}